The neutrophil protein S100A12 is associated with a comprehensive ultrasonographic synovitis score in a longitudinal study of patients with rheumatoid arthritis treated with adalimumab

The calcium-binding protein S100A12 correlates with measures of disease activity in patients with rheumatoid arthritis (RA). The protein reflects neutrophil activation and the present objective was to explore in a pilot study the associations between S100A12 and other inflammatory markers, clinical...

Full description

Saved in:
Bibliographic Details
Published in:BMC musculoskeletal disorders 2014-10, Vol.15 (1), p.335-335, Article 335
Main Authors: Nordal, Hilde Haugedal, Brun, Johan G, Halse, Anne-Kristine, Jonsson, Roland, Fagerhol, Magne K, Hammer, Hilde Berner
Format: Article
Language:English
Subjects:
Adalimumab
Adult
Aged
Antibodies, Monoclonal, Humanized - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - diagnostic imaging
Biomarkers - blood
Drug therapy
Female
Follow-Up Studies
Humans
Longitudinal Studies
Male
Medical research
Middle Aged
Musculoskeletal diseases
Neutrophils
NMR
Nuclear magnetic resonance
Pilot Projects
Rheumatoid arthritis
S100 Proteins - blood
S100A12 Protein
Synovitis - blood
Synovitis - diagnostic imaging
Treatment Outcome
Ultrasonography
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The calcium-binding protein S100A12 correlates with measures of disease activity in patients with rheumatoid arthritis (RA). The protein reflects neutrophil activation and the present objective was to explore in a pilot study the associations between S100A12 and other inflammatory markers, clinical assessments as well as degree of synovitis detected by a comprehensive ultrasonography (US) examination in RA patients during biologic treatment. Twenty patients with RA were examined clinically and by use of US as well as laboratory markers S100A12, calprotectin, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) before starting adalimumab, with follow-up after 1, 3, 6 and 12 months. Ultrasonographic B-mode (BM) and power Doppler (PD) assessments of 78 joints, 36 tendons/tendon groups and 2 bursas were performed, and sum US scores calculated. Wilcoxon signed rank test assessed treatment response and Spearman rank correlation test was used to calculate correlations. The concentrations of S100A12 decreased after 3 months (p 
ISSN:1471-2474
1471-2474
DOI:10.1186/1471-2474-15-335